Search

Search

このページは機械翻訳されています。他のページは英語で表示される場合があります。 View in English

ホーム
...
研究分野生物医学と臨床科学腫瘍学とがん発生分子標的
EGFR陽性肺腺癌の症例が,一度小細胞癌に変異したが,再び腺癌に悪化した.

EGFR陽性肺腺癌の症例が,一度小細胞癌に変異したが,再び腺癌に悪化した.

Satoshi Tanaka ¹, Kento Yokota ¹, Nobuaki Yoshimura ¹, Satoshi Tobita ¹, Moto Yaga ¹, Kiyonobu Ueno ¹

Satoshi Tanaka ¹, Kento Yokota ¹, Nobuaki Yoshimura ¹

¹Department of Respiratory Medicine, Osaka General Medical Center, Osaka, Japan.

⁰Department of Respiratory Medicine, Osaka General Medical Center, Osaka, Japan.

Respiratory Medicine Case Reports +

|

2025年9月2日

関連する実験動画

These videos have been matched automatically. Contact us if they are not relevant.

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

See all related videos

PubMedで要約を見る

まとめ

この要約は機械生成です。

肺がんにおけるEGFR- TKIsに対する獲得抵抗は,小細胞肺がん (SCLC) への変異を伴う可能性があります. このような複雑な症例の正確な診断と適切な治療には繰り返し生検と腫瘍マーカー分析が不可欠です

科学分野

腫瘍学
分子生物学
遺伝学

背景

Epidermal成長因子受容体 (EGFR) - タイロシンキナーゼ阻害剤 (TKIs) は,EGFR変異性非小細胞肺がん (NSCLC) の進行において不可欠である.
EGFR- TKIsに対する得られた耐性は,NSCLCの管理において重要な臨床的課題である.
小細胞肺がん (SCLC) の変異は,獲得抵抗メカニズムの約10%を占めています.

キーワード:

Epidermal成長因子受容体チロシンキナーゼ阻害剤 (EGFR-TKI) リバイオプシー小細胞肺がん (SCLC) 変形する腫瘍マーカー

関連する実験動画

自動的に一致したビデオです Contact us もしそれらが関連していない場合

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

See all related videos

Share

X
Facebook
LinkedIn
YouTube

ABOUT JoVE

Overview
Leadership
Blog
JoVE Help Center

AUTHORS

Publishing Process
Editorial Board
Scope & Policies
Peer Review
FAQ
Submit

LIBRARIANS

Testimonials
Subscriptions
Access
Resources
Library Advisory Board
FAQ

RESEARCH

JoVE Journal
Methods Collections
JoVE Encyclopedia of Experiments
Archive

EDUCATION

JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Faculty Resource Center
Faculty Site

Terms & Conditions of Use
Privacy Policy
Policies